С.Цогтсайхан
Loading...
Товч нэр
С.Цогтсайхан
Бүтэн нэр
Сандаг Цогтсайхан
Латин нэр
Sandag Tsogtsaikhan
Эрдмийн цол
Профессор
Боловсролын зэрэг
Доктор (Ph.D)
Харьяалал
ORCID
Scopus Author ID
2 results
Now showing 1 - 2 of 2
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Impact of Booster Vaccination on Infection and Hospitalization Rates during the Mass Vaccination in Mongolia(Mongolian National University of Medical Sciences, 2025-09-30); ; ; ; Objective: Our study aims to evaluate the effectiveness of booster vaccination in preventing new COVID-19 infections and related hospitalizations among groups that received the primary vaccination series. Methods: Booster vaccination started on August 31, 2021, at recruitment in May 2022. By May 2022, 64% of the Mongolian population had received two primary doses of a COVID-19 vaccine, and 31% had received a booster dose. We followed 1,251 participants (459 males and 792 females, with a mean age of 41.5 ± 14.5 years [18–93], and a median age of 39.0 years) over six months, from the start of booster immunization on September 1, 2021, to February 28, 2022. We compared infection and hospitalization rates among vaccinated groups using logistic regression and calculated vaccine effectiveness (VE) for booster recipients with the formula: VE = 1 – (vaccinated rate/unvaccinated rate) × 100. Results: All participants received two doses of one of four vaccines used in the nationwide campaign. During the study period, we identified 449 new infection cases, accounting for 35.9% of all participants, and 150 subsequent hospitalizations, or 12.0% of the total. Participants who did not receive a booster demonstrated significantly higher infection rates compared to those who did. Booster vaccination provided notably better protection against new infections among frontline workers and reduced hospitalizations in high-risk groups. No significant differences were found in VE when comparing participants based on seroconversion after initial vaccination or the type of booster vaccine used.Conclusion: Therefore, we concluded that COVID-19 booster vaccinations effectively enhanced protection against new SARS-CoV-2 infections among frontline healthcare workers, government employees, and individuals at higher risk for severe disease, thereby reducing their risk of hospitalization. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Cerebral cystic echinococcosis in Mongolian children caused by Echinococcus canadensis(2018-10) ;Shirmen, Orkhontuul ;Batchuluun, Batbold ;Lkhamjav, Avaajigmed ;Tseveen, TugbayarMunkhjargal, TsetsegdelgerRecent molecular re-evaluation of Echinococcus granulosus, which causes cystic echinococcosis (CE), has revealed that it is not a single species, but instead consists of 5 cryptic species. Among them, E. granulosus (dog-sheep strain) is predominant (75%) followed by Echinococcus canadensis (22%). The major affected organs, in humans, are the liver (88%) and lungs (11%). Primary cerebral CE comprises less than 1% of all cases. As cerebral CE cases are rare, there are few reports with molecular confirmation of the causative species. This study reports mitochondrial gene analysis from 4 Mongolian pediatric cerebral CE cases. Molecular confirmation was obtained for 3 of the 4 cases, with all 3 cases determined to be due to E. canadensis (G6/G7) infection. None of the cases had other organ involvement. This is only the third report on the molecular identification of the Echinococcus species responsible for cerebral CE, and only the second report of E. canadensis (G6/G7) being the causative agent of cerebral CE.Scopus© Citations 14
